Clarke S - Search Results

1

Plasma pre-treatment T790M relative allelic frequency in patients with advanced EGFR-mutated non-small cell lung cancer predicts treatment response to subsequent-line osimertinib.

Ding PN, Roberts TL, Chua W, Becker TM, Caixeiro N, de Souza P, Gao B, Lee CK, Itchins M, Westman H, Clarke S, Blinman P, Kao S, John T, Leal JL, Bray VJ. Ding PN, et al. Among authors: clarke s. Transl Lung Cancer Res. 2021 Apr;10(4):1623-1634. doi: 10.21037/tlcr-20-1125. Transl Lung Cancer Res. 2021. PMID: 34012779 Free PMC article.

2

Carboplatin and vinorelbine in untreated locally advanced and metastatic non-small cell lung cancer.

Horvath L, Boyer M, Clarke S, Beale P, Beith J, Underhill C, Stockler M, Bishop J. Horvath L, et al. Among authors: clarke s. Lung Cancer. 2001 May;32(2):173-8. doi: 10.1016/s0169-5002(00)00218-x. Lung Cancer. 2001. PMID: 11325488 Review.

3

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.

Chua W, Goldstein D, Lee CK, Dhillon H, Michael M, Mitchell P, Clarke SJ, Iacopetta B. Chua W, et al. Among authors: clarke sj. Br J Cancer. 2009 Sep 15;101(6):998-1004. doi: 10.1038/sj.bjc.6605239. Epub 2009 Aug 11. Br J Cancer. 2009. PMID: 19672255 Free PMC article.

4

Cetuximab-associated pulmonary toxicity.

Chua W, Peters M, Loneragan R, Clarke S. Chua W, et al. Among authors: clarke s. Clin Colorectal Cancer. 2009 Apr;8(2):118-20. doi: 10.3816/CCC.2009.n.019. Clin Colorectal Cancer. 2009. PMID: 19739274

5

Predictive markers for haematological toxicity of pemetrexed.

Kao SC, Phan VH, Clarke SJ. Kao SC, et al. Among authors: clarke sj. Curr Drug Targets. 2010 Jan;11(1):48-57. doi: 10.2174/138945010790031072. Curr Drug Targets. 2010. PMID: 19839928 Review.

6

Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer.

Chua W, Moore MM, Charles KA, Clarke SJ. Chua W, et al. Curr Opin Mol Ther. 2009 Dec;11(6):611-22. Curr Opin Mol Ther. 2009. PMID: 20072938 Review.

7

Adjuvant chemotherapy for early colon cancer: what survival benefits make it worthwhile?

Blinman P, Duric V, Nowak AK, Beale P, Clarke S, Briscoe K, Boyce A, Goldstein D, Hudson M, Stockler M. Blinman P, et al. Among authors: clarke s. Eur J Cancer. 2010 Jul;46(10):1800-7. doi: 10.1016/j.ejca.2009.12.032. Eur J Cancer. 2010. PMID: 20137908

8

Inflammation and cancer: causes and consequences.

Moore MM, Chua W, Charles KA, Clarke SJ. Moore MM, et al. Among authors: clarke sj. Clin Pharmacol Ther. 2010 Apr;87(4):504-8. doi: 10.1038/clpt.2009.254. Epub 2010 Feb 10. Clin Pharmacol Ther. 2010. PMID: 20147899 Review.

9

Malignant mesothelioma.

Kao SC, Reid G, Lee K, Vardy J, Clarke S, van Zandwijk N. Kao SC, et al. Among authors: clarke s. Intern Med J. 2010 Nov;40(11):742-50. doi: 10.1111/j.1445-5994.2010.02223.x. Intern Med J. 2010. PMID: 20298508 Review.

10

Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer.

Chua W, Kho PS, Moore MM, Charles KA, Clarke SJ. Chua W, et al. Among authors: clarke sj. Crit Rev Oncol Hematol. 2011 Sep;79(3):224-50. doi: 10.1016/j.critrevonc.2010.07.012. Epub 2010 Aug 16. Crit Rev Oncol Hematol. 2011. PMID: 20719530 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,786 results

Search Page